Labcorp Q3 2026 Revenue Rises to $3.81 Billion, Diluted EPS $3.22
Labcorp (NYSE: LH) reported Q3 2026 revenue of $3.81B, up from $3.56B a year earlier, with diluted EPS of $3.22 vs. $3.12. Net earnings were $262.8M, up from $261.1M. Nine-month revenue rose to $11.08B, with net earnings of $839.3M and diluted EPS of $10.22.
How this was made
The 30-second read
Why it matters
The earnings beat suggests a short‑term bullish bias for LH, though cost increases may temper enthusiasm.
Market read
First‑report earnings release for a large‑cap health‑care company; provides fresh data for traders.
What to watch
Rising interest expense and higher amortization costs could pressure margins despite revenue growth.
Background
Labcorp filed its Form 10‑Q for the quarter ended September 30, 2026, disclosing detailed financial results.
Ticker impact
Labcorp Holdings reported Q3 2026 revenue of $3.81 B (up 7% YoY) and diluted EPS of $3.22, both higher than the prior-year period.
likely modest upside as the market prices in the revenue and earnings growth
The company posted solid top‑line growth and EPS improvement, exceeding the prior-year results, which typically supports a short‑term price lift.
Market effects
Healthcare services earnings may lift peer diagnostic and lab companies.
U.S. market may see a slight gain in the health‑care sector.
Limited; primarily affects U.S. listed health‑care stocks.
Counterpoint
If investors had already priced in the modest growth, the reaction could be muted or negative.
Key entities
- companyLabcorp Holdings Inc.
U.S. clinical laboratory services provider.
